The U.S. Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity. Tirzepatide, the active ingredient in Zepbound, is already approved under the trade name Mounjaro to be used along with diet and exercise to help improve blood sugar in adults with type 2 diabetes mellitus.
Eli Lilly said the obesity medicine, which helped adults in clinical studies lose about 20% of their body weight, will be available in the U.S. by the end of the year. The list price will be $1,060.
InlandNewsToday is the one-stop online source for same-day news and events occurring in Riverside and San Bernardino counties in Southern California featuring news, traffic information, real-time weather and things to do, all this offered in text and webcasts/podcasts.
The Food and Drug Administration has authorized Zepbound, which is manufactured by Eli Lilly, approval to be prescribed as a weight-management treatment, paving the way for more people to gain access to the medication.